Vial system integrity and lack of sterility assurance are some of the leading causes of parenteral drug product recalls from a regulatory and patient safety perspective. According to USP 1207, “Inherent package integrity is a measure of the leak tightness of a container-closure system, given anticipated variables of material composition, dimension, processing, assembly, package storage, distribution and use.” It can be challenging for pharmaceutical companies to develop truly integral vial systems due to limited knowledge surrounding container closure integrity (CCI) and sufficient data on primary packaging component variability. This webinar will focus on:

The regulatory expectations for container closure integrity (CCI).

Historic market challenges with sterile vial systems.

A new approach to container closure selection that utilizes component dimensional variability and big data

The DeltaCube™ Modeling Platform from West Pharmaceutical Services will also be introduced. This platform uses component dimensional data as a leading indicator to rapidly evaluate multiple CCSs. It also provides initial processing targets for rubber stopper compression and computes the most likely distribution of seal metal skirt length that will be available to crimp. The talk will detail how the platform complements a robust Quality by Design (QbD) approach to package development and links component selection, capping optimization and CCI to mitigate risk to vial system integrity, using both predictive and confirmatory assurance techniques. This can result in significant time savings when selecting CCS components, optimizing capping processes and predicting future vial system performance.